Publications by authors named "R Sandin"
Importance: Clarifying the underutilization of treatment intensification (TI) for metastatic castration-sensitive prostate cancer (mCSPC) may improve implementation of evidence-based medicine and survival outcomes.
Objective: To investigate physicians' beliefs about TI in mCSPC to understand the gap between evidence-based guidelines and clinical practice.
Design, Setting, And Participants: This survey study analyzed data from the Adelphi Real World retrospective survey, which comprised physician surveys that were linked to medical record reviews of US adult patients treated for mCSPC between July 2018 and January 2022.
Article Synopsis
- The study aimed to assess how palbociclib treatment affects health-related quality of life (HRQoL) in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer through a systematic review of literature up to June 2023.
- A total of 15 studies, including randomized controlled trials and real-world evidence studies, indicated that HRQoL is generally maintained or even improved in patients treated with palbociclib compared to monotherapy.
- The findings showed consistent positive effects on individual patient outcomes like pain and fatigue, with comparable results across diverse patient groups, suggesting that HRQoL is largely preserved when palbociclib is added to endocrine therapy.
Article Synopsis
- This study analyzes breast cancer-specific survival (BCSS) in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients, focusing on changes after the introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in 2015.
- Researchers used SEER registry data from 11,467 HR+/HER2- mBC patients, finding a 10% reduction in risk of BC-specific death for those diagnosed post-2015 compared to those diagnosed pre-2015, indicating improved survival due to CDK4/6i.
- In contrast, no significant improvements in BC
Background: Previous studies have shown that Black men receive worse prostate cancer care than White men. This has not been explored in metastatic castration-sensitive prostate cancer (mCSPC) in the current treatment era.
Methods: We evaluated treatment intensification (TI) and overall survival (OS) in Medicare (2015-2018) and Veterans Health Administration (VHA; 2015-2019) patients with mCSPC, classifying first-line mCSPC treatment as androgen deprivation therapy (ADT) + novel hormonal therapy; ADT + docetaxel; ADT + first-generation nonsteroidal antiandrogen; or ADT alone.
Article Synopsis
- Nirmatrelvir/ritonavir (NMV/r) is a treatment for mild-to-moderate COVID-19 in high-risk adults and has also been approved for certain pediatric patients by the FDA.
- The study aims to evaluate the annual budget impact of NMV/r within a US commercial health plan during the Omicron variant's prevalence.
- Results show that NMV/r could potentially reduce hospitalizations significantly, leading to a total budget impact of approximately $2.7 million, with additional cost savings when considering various post-COVID conditions.